article Open AccessTop 1% cited
mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials
Vaccine · 2019 · Vol. 37(25) · pp. 3326–3334
Robert FeldmanRainard Fuhr(PAREXEL International (United Kingdom))Igor Smolenov(Moderna Therapeutics (United States))Amilcar Ribeiro(Moderna Therapeutics (United States))Lori Panther(Moderna Therapeutics (United States))Michael Watson✉(Moderna Therapeutics (United States))Joseph J. Senn(Moderna Therapeutics (United States))Mike Smith(Moderna Therapeutics (United States))Örn Almarsson(Moderna Therapeutics (United States))Hari Pujar(Moderna Therapeutics (United States))Michael E. Laska(Moderna Therapeutics (United States))James D. Thompson(Moderna Therapeutics (United States))Tal Zaks(Moderna Therapeutics (United States))Giuseppe Ciaramella(Moderna Therapeutics (United States))
Abstract
The first mRNA vaccines against H10N8 and H7N9 influenza viruses were well tolerated and elicited robust humoral immune responses. ClinicalTrials.gov NCT03076385 and NCT03345043.
Influenza Virus Research StudiesRespiratory viral infections researchSARS-CoV-2 and COVID-19 ResearchVirologyPandemicPandemic influenzaImmunogenicityBiologyInfluenza A virusMedicineClinical trialCoronavirus disease 2019 (COVID-19)Immunology
MeSH terms
Immunogenicity, VaccineAdolescentAdultAntibodies, ViralDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansInfluenza, HumanInfluenza VaccinesMaleMiddle AgedRNA, ViralYoung AdultHealthy Volunteers
Citations
456
FWCI
42.95
field-weighted impact
References
37
Percentile
100%
vs. same field & year
Citations per year
Cited by
mRNA vaccines manufacturing: Challenges and bottlenecks
Vaccine · 2021 · 488 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.